Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-18

Study Completion Date

2030-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

NCT07299331

Marginal Zone Lymphoma(MZL)

NOT_YET_RECRUITING NA

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

NCT05504603

Untreated Mantle Cell Lymphoma

UNKNOWN PHASE2

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

NCT03846427

Marginal Zone Lymphoma MZL

COMPLETED PHASE2

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

NCT04460248

Diffuse Large B Cell Lymphoma

ACTIVE_NOT_RECRUITING PHASE2

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

NCT04938297

Central Nervous System Lymphoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Marginal Zone Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zanubrutinib Combined With Rituximab

Induction treatment:

Rituximab, 375mg/m2, Intravenous administration on day 1 (21 days/cycle); Zanubrutinib, 160mg twice daily continuous oral administration from 1 to 8 cycles (21 days/cycle)

Maintenance treatment:

Zanubrutinib, 160mg twice daily continuous oral administration for two years (28 days/cycle)

Zanubrutinib

Intervention Type DRUG

160mg twice daily continuous oral administration.

Rituximab

Intervention Type DRUG

375mg/m2, Intravenous administration on day 1 of each 3-week cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zanubrutinib

160mg twice daily continuous oral administration.

Intervention Type DRUG

Rituximab

375mg/m2, Intravenous administration on day 1 of each 3-week cycle

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zanubrutinib pills RiTUXimab Injection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with CD20-positive marginal zone lymphoma diagnosed by histopathology
2. First-line treatment with the combination regimen of zanubrutinib and rituximab
3. No receiving systematic treatment before enrollment
4. Having at least one measurable lesions. Measurable lesions were defined as: the longest diameter of lymph node lesions in CT cross-sectional images \> 1.5 cm, or the longest diameter of the extranodal lesion is greater than 1.0cm
5. The patients voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.

Exclusion Criteria

1. Other malignant tumor history or active malignant tumor need be treated
2. In addition to zanubrutinib and rituximab, other anti-tumor drug treatments were also received simultaneously (except for glucocorticoids aimed at controlling symptoms before formal treatment).

Eligible Sex

ALL

Accepts Healthy Volunteers

No